Chemoprevention of human skin cancer

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

The incidence of skin cancer has been rising in recent years with significant effects on public health. Primary prevention has proven inadequate in impacting the incidence of skin cancer, thus stimulating the development of chemopreventive strategies. The majority of skin cancer chemoprevention studies focus on occurrence of new nonmelanoma skin cancers (NMSC) in individuals with a previous NMSC, or on reduction in the number of premalignant skin lesions such as actinic keratoses (AK). Dysplastic nevi, a likely precursor of melanoma, are also potential targets for chemoprevention strategies. Premalignant lesions are especially attractive as endpoints since they are more common than frank cancer, resulting in reduced sample size, length, and cost of clinical trials. Development of new agents that affect the pathogenesis of skin cancer will be discussed, from elucidation of molecular targets to implementation of trials designed to determine the effects of chemopreventive interventions on human skin cancer.

Original languageEnglish (US)
Pages (from-to)269-285
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume41
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Chemoprevention
Skin Neoplasms
Dysplastic Nevus Syndrome
Actinic Keratosis
Incidence
Primary Prevention
Sample Size
Melanoma
Public Health
Clinical Trials
Costs and Cost Analysis
Skin
Neoplasms

Keywords

  • Actinic keratosis (AK)
  • Chemoprevention
  • Chemoprevention agents
  • Nonmelanoma skin cancer (NMSC)

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Chemoprevention of human skin cancer. / Einspahr, Janine G; Stratton, Steven P; Bowden, G. Timothy; Alberts, David S.

In: Critical Reviews in Oncology/Hematology, Vol. 41, No. 3, 2002, p. 269-285.

Research output: Contribution to journalArticle

@article{ce937243e8624bf490014cdb265605ed,
title = "Chemoprevention of human skin cancer",
abstract = "The incidence of skin cancer has been rising in recent years with significant effects on public health. Primary prevention has proven inadequate in impacting the incidence of skin cancer, thus stimulating the development of chemopreventive strategies. The majority of skin cancer chemoprevention studies focus on occurrence of new nonmelanoma skin cancers (NMSC) in individuals with a previous NMSC, or on reduction in the number of premalignant skin lesions such as actinic keratoses (AK). Dysplastic nevi, a likely precursor of melanoma, are also potential targets for chemoprevention strategies. Premalignant lesions are especially attractive as endpoints since they are more common than frank cancer, resulting in reduced sample size, length, and cost of clinical trials. Development of new agents that affect the pathogenesis of skin cancer will be discussed, from elucidation of molecular targets to implementation of trials designed to determine the effects of chemopreventive interventions on human skin cancer.",
keywords = "Actinic keratosis (AK), Chemoprevention, Chemoprevention agents, Nonmelanoma skin cancer (NMSC)",
author = "Einspahr, {Janine G} and Stratton, {Steven P} and Bowden, {G. Timothy} and Alberts, {David S}",
year = "2002",
doi = "10.1016/S1040-8428(01)00185-8",
language = "English (US)",
volume = "41",
pages = "269--285",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Chemoprevention of human skin cancer

AU - Einspahr, Janine G

AU - Stratton, Steven P

AU - Bowden, G. Timothy

AU - Alberts, David S

PY - 2002

Y1 - 2002

N2 - The incidence of skin cancer has been rising in recent years with significant effects on public health. Primary prevention has proven inadequate in impacting the incidence of skin cancer, thus stimulating the development of chemopreventive strategies. The majority of skin cancer chemoprevention studies focus on occurrence of new nonmelanoma skin cancers (NMSC) in individuals with a previous NMSC, or on reduction in the number of premalignant skin lesions such as actinic keratoses (AK). Dysplastic nevi, a likely precursor of melanoma, are also potential targets for chemoprevention strategies. Premalignant lesions are especially attractive as endpoints since they are more common than frank cancer, resulting in reduced sample size, length, and cost of clinical trials. Development of new agents that affect the pathogenesis of skin cancer will be discussed, from elucidation of molecular targets to implementation of trials designed to determine the effects of chemopreventive interventions on human skin cancer.

AB - The incidence of skin cancer has been rising in recent years with significant effects on public health. Primary prevention has proven inadequate in impacting the incidence of skin cancer, thus stimulating the development of chemopreventive strategies. The majority of skin cancer chemoprevention studies focus on occurrence of new nonmelanoma skin cancers (NMSC) in individuals with a previous NMSC, or on reduction in the number of premalignant skin lesions such as actinic keratoses (AK). Dysplastic nevi, a likely precursor of melanoma, are also potential targets for chemoprevention strategies. Premalignant lesions are especially attractive as endpoints since they are more common than frank cancer, resulting in reduced sample size, length, and cost of clinical trials. Development of new agents that affect the pathogenesis of skin cancer will be discussed, from elucidation of molecular targets to implementation of trials designed to determine the effects of chemopreventive interventions on human skin cancer.

KW - Actinic keratosis (AK)

KW - Chemoprevention

KW - Chemoprevention agents

KW - Nonmelanoma skin cancer (NMSC)

UR - http://www.scopus.com/inward/record.url?scp=0036008997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036008997&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(01)00185-8

DO - 10.1016/S1040-8428(01)00185-8

M3 - Article

C2 - 11880204

AN - SCOPUS:0036008997

VL - 41

SP - 269

EP - 285

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -